<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Likelihood of congenital syphilis infection in newborn infants born to mothers with reactive nontreponemal and treponemal tests during pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Likelihood of congenital syphilis infection in newborn infants born to mothers with reactive nontreponemal and treponemal tests during pregnancy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Likelihood of congenital syphilis infection in newborn infants born to mothers with reactive nontreponemal and treponemal tests during pregnancy</div><div class="cntnt"><table cellspacing="0"><colgroup width="12%"></colgroup><colgroup span="4" width="22%"></colgroup> <tbody> <tr> <td class="subtitle1">Category</td> <td class="subtitle1">Definition</td> <td class="subtitle1">Additional evaluation to perform</td> <td class="subtitle1">Treatment</td> <td class="subtitle1">Follow-up testing<br/> (applies to all categories)</td> </tr> <tr> <td>Proven or highly probable</td> <td> <ul> <li>Mother diagnosed with syphilis during pregnancy (reactive nontreponemal and treponemal tests), regardless of treatment received</li> <p class="extra_spacing"><strong>Plus</strong></p> <li>Newborn has <strong>ANY</strong> of the following: <ul> <li>Clinical findings consistent with congenital syphilis*</li> <li>Infant serum VDRL or RPR titer ≥4-fold maternal titer<sup>¶</sup></li> <li>Positive darkfield microscopy, DFA, or PCR of skin lesions, body fluid(s), placenta, or umbilical cord<sup>Δ</sup></li> </ul> </li> </ul> </td> <td> <ul> <li>LP for CSF cell count, protein, and CSF VDRL</li> <li>CBC with differential and platelet count</li> <li>LFTs</li> <li>Long-bone radiographs</li> <li>ABR</li> <li>Eye examination</li> <li>Other tests as clinically indicated: <ul> <li>Chest radiograph if there are pulmonary findings</li> <li>Neuroimaging if there are concerning neurologic findings</li> <li>Abdominal imaging if there is significant organomegaly</li> </ul> </li> </ul> </td> <td>10 days of IV penicillin G</td> <td rowspan="6"> <ul> <li>Monitor clinical examination for development of new concerning findings</li> <li>Perform follow-up serologic testing: <ul> <li>For infants with <strong>reactive</strong> nontreponemal serologies: Perform serial serologic testing with VDRL or RPR (use same test as for initial testing) at 1, 2, 4, 6, and 12 months or until nonreactive. If nontreponemal tests are still positive at 6-12 months, the infant should be re-evaluated (including LP) and treated with an extended course of parenteral penicillin.</li> <li>For infants with <strong>nonreactive</strong> nontreponemal serologies: Recheck VDRL or RPR (use same test as for initial testing) at age 3 months to confirm infant remains seronegative.</li> </ul> </li> </ul> </td> </tr> <tr> <td rowspan="3">Possible</td> <td rowspan="3"><strong>ALL</strong> of the following: <ul> <li>Mother diagnosed with syphilis during pregnancy (reactive nontreponemal and treponemal tests)</li> <li>Mother did not receive treatment, or received inadequate/suboptimal treatment, or had evidence of relapse or reinfection<sup>◊</sup></li> <li>Infant physical examination is normal</li> <li>Infant serum VDRL or RPR titer &lt;4-fold maternal titer<sup>¶</sup></li> </ul> </td> <td colspan="2">We further classify newborns in the "possible" category as higher or lower risk: <ul> <li><strong>Higher risk:</strong> Neonate's VDRL or RPR is reactive <strong>or</strong> maternal risk of untreated syphilis is high</li> <li><strong>Lower risk:</strong> Neonate's VDRL or RPR is nonreactive <strong>and</strong> maternal risk of untreated syphilis is low</li> </ul> </td> </tr> <tr> <td><strong>Higher risk:</strong> <ul> <li>Perform same evaluation as for the "proven or highly probable" category (see above)<sup>§</sup></li> </ul> </td> <td><strong>Higher risk:</strong> <ul> <li>If any part of the additional evaluation is abnormal, not performed, or uninterpretable (eg, traumatic LP) or if follow-up is uncertain: 10 days of IV penicillin G</li> <li>If all tests in the additional evaluation are performed and are normal: Single dose of IM penicillin benzathine</li> </ul> </td> </tr> <tr> <td><strong>Lower risk:</strong> <ul> <li>Additional evaluation is <strong>not</strong> necessary</li> </ul> </td> <td><strong>Lower risk:</strong> <ul> <li>Single dose of IM benzathine penicillin</li> </ul> </td> </tr> <tr> <td>Less likely</td> <td><strong>ALL</strong> of the following: <ul> <li>Mother diagnosed with syphilis during pregnancy (reactive nontreponemal and treponemal tests)</li> <li>Mother received appropriate treatment <strong>during</strong> pregnancy (at least 4 weeks before delivery)<sup>◊</sup></li> <li>Mother has no evidence of reinfection or relapse<sup>◊</sup></li> <li>Infant physical examination is normal</li> <li>Infant serum VDRL or RPR titer &lt;4-fold maternal titer<sup>¶</sup></li> </ul> </td> <td>Not required</td> <td>Single dose of IM penicillin benzathine<sup>¥</sup></td> </tr> <tr> <td>Unlikely</td> <td><strong>ALL</strong> of the following: <ul> <li>Mother had reactive nontreponemal and treponemal tests during pregnancy</li> <li>Mother received appropriate treatment <strong>before</strong> pregnancy<sup>◊</sup></li> <li>Mother's titers remained low (VDRL &lt;1:2; RPR &lt;1:4) and stable before and during pregnancy and at delivery</li> <li>Infant physical examination is normal</li> <li>Infant serum VDRL or RPR titer &lt;4-fold maternal titer<sup>¶</sup></li> </ul> </td> <td>Not required</td> <td>Not required<sup>‡</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes the likelihood of congenital syphilis infection based upon maternal and newborn serologies, adequacy of maternal treatment, clinical findings in the infant, and other findings. Evaluation for congenital syphilis is warranted in all newborns born to mothers who have reactive nontreponemal and treponemal tests for syphilis during pregnancy. For mothers screened with the traditional approach, the treponemal test is necessary to exclude a false-positive nontreponemal result. When reverse sequencing is used, the nontreponemal test is still necessary for comparison with the mother's result and for monitoring of treatment success (two nontreponemal tests are needed when there is discordance between syphilis antibody and nontreponemal test during reverse sequencing). Refer to UpToDate's topics on syphilis during pregnancy and congenital syphilis for additional details.</div><div class="graphic_footnotes"><p>VDRL: venereal disease research laboratory; RPR: rapid plasma regain; DFA: direct fluorescent antibody; PCR: polymerase chain reaction; LP: lumbar puncture; CBC: complete blood count; LFTs: liver function tests; ABR: auditory brainstem response; CDC: Centers for Disease Control and Prevention; CSF: cerebrospinal fluid; IM: intramuscular; IV: intravenous.</p>
<p>* Findings of congenital syphilis may include hepatosplenomegaly, rash, condyloma lata, snuffles, jaundice (nonviral hepatitis), pseudoparalysis, pallor (anemia), or edema (nephrotic syndrome and/or malnutrition). Refer to UpToDate topic on congenital syphilis for additional details.</p>
<p>¶ A 4-fold titer is equivalent to two dilutions (eg, newborn's titer 1:32 if maternal titer is 1:8).</p>
<p>Δ These tests are not available in many clinical settings.</p>
◊ Adequate treatment is defined as completion of a penicillin-based regimen, in accordance with CDC treatment guidelines, appropriate for stage of infection and initiated ≥4 weeks before delivery. Relapse or reinfection after treatment is suggested by a 4-fold increase of maternal VDRL or RPR titers after treatment. Inadequate/suboptimal therapy includes <strong>any</strong> of the following:
<ul>
<li>Treatment with a nonpenicillin antibiotic</li>
<li>Treatment given &lt;4 weeks before delivery</li>
<li>Inappropriate dose for stage of disease</li>
<li>Inadequate documentation of maternal treatment</li>
<li>Inadequate response to therapy (ie, maternal VDRL or RPR titers did not decline at least 4-fold after treatment)</li>
</ul>
<p class="extra_spacing">§ The CDC guidelines include a caveat that additional evaluation may not be necessary for neonates in the "possible" category if a 10-day treatment course is planned. Nevertheless, we suggest performing the evaluation in higher-risk neonates (as defined above) since the evaluation may inform decisions regarding treatment and follow-up.</p>
<p>¥ Some specialists opt not to treat infants in this category and instead provide close (ie, monthly) serologic follow-up. If this approach is chosen, treatment should be provided if the infant's titers do not decline as expected over the first few months after birth.</p>
‡ If follow-up is uncertain, some specialists would provide a single dose of IM benzathine penicillin to protect the infant in the unlikely event that the mother was reinfected.</div><div id="graphicVersion">Graphic 140142 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
